{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:25:32Z","timestamp":1791480332917,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-024-20841-x","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:08:00Z","timestamp":1733216880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Implementation of the advanced HIV disease package of care using a public health approach: lessons from Nigeria"],"prefix":"10.1186","volume":"24","author":[{"given":"Williams","family":"Eigege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oche","family":"Agbaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nere","family":"Otubu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opeyemi","family":"Abudiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwakemi","family":"Sowale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boma","family":"Levy-Braide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asari","family":"Inyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Rathakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikechukwu","family":"Amamilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folu","family":"Lufadeju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Amole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owens","family":"Wiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Onotu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Sanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nwaokenneya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Patiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akudo","family":"Ikpeazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Oguche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Oladele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaimon","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"20841_CR1","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy [Internet]. 2017 [cited 2022 Nov 16]. https:\/\/www.who.int\/publications-detail-redirect\/9789241550062"},{"key":"20841_CR2","unstructured":"Joint United Nations Programme on HIV and AIDS. AIDSinfo | UNAIDS [Internet]. [cited 2023 Jun 7]. https:\/\/aidsinfo.unaids.org\/"},{"issue":"12","key":"20841_CR3","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/cid\/cis797","volume":"55","author":"AS Walker","year":"2012","unstructured":"Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis off Publ Infect Dis Soc Am. 2012;55(12):1707\u201318.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"20","key":"20841_CR4","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1001\/jama.286.20.2568","volume":"286","author":"RS Hogg","year":"2001","unstructured":"Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O\u2019Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568\u201377.","journal-title":"JAMA"},{"issue":"9327","key":"20841_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","volume":"360","author":"M Egger","year":"2002","unstructured":"Egger M, May M, Ch\u00eane G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet Lond Engl. 2002;360(9327):119\u201329.","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"20841_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/jcm10040716","volume":"10","author":"J Portilla-Tamarit","year":"2021","unstructured":"Portilla-Tamarit J, Reus S, Portilla I, Fuster Ruiz-de-Apodaca MJ, Portilla J. Impact of Advanced HIV Disease on Quality of Life and Mortality in the era of combined antiretroviral treatment. J Clin Med. 2021;10(4):716.","journal-title":"J Clin Med"},{"issue":"Suppl 2","key":"20841_CR7","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1093\/cid\/cix1138","volume":"66","author":"A Calmy","year":"2018","unstructured":"Calmy A, Ford N, Meintjes G. The Persistent Challenge of Advanced HIV Disease and AIDS in the era of antiretroviral therapy. Clin Infect Dis off Publ Infect Dis Soc Am. 2018;66(Suppl 2):S103\u2013SS105.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"3","key":"20841_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/QAD.0000000000003442","volume":"37","author":"J PATTEN GE, EUVRARD","year":"2023","unstructured":"PATTEN GE, EUVRARD J, ANDEREGG N, BOULLE A, ARENDSE KD, VON-DER HEYDEN E, et al. Advanced HIV disease and engagement in care among patients on antiretroviral therapy in South Africa: results from a multi-state model. AIDS Lond Engl. 2023;37(3):513\u201322.","journal-title":"AIDS Lond Engl"},{"key":"20841_CR9","unstructured":"Barriers and facilitators to implementing Advanced HIV Disease screening at secondary referral hospital -Malawi. Asequential exploratory mixed method-study - PMC [Internet]. [cited 2024 Oct 14]. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10055552\/"},{"key":"20841_CR10","unstructured":"Global tuberculosis. report 2019 [Internet]. [cited 2023 Feb 16]. https:\/\/www.who.int\/publications-detail-redirect\/9789241565714"},{"issue":"8","key":"20841_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis"},{"key":"20841_CR12","unstructured":"Prevalence of Histoplasmosis among Persons with Advanced HIV Disease. Nigeria - PMC [Internet]. [cited 2024 Sep 26]. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9622240\/"},{"issue":"7","key":"20841_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/jof9070757","volume":"9","author":"P Sekar","year":"2023","unstructured":"Sekar P, Nalintya E, Kwizera R, Mukashyaka C, Niyonzima G, Namakula LO, et al. Prevalence of Histoplasma Antigenuria among Outpatient Cohort with Advanced HIV in Kampala, Uganda. J Fungi. 2023;9(7):757.","journal-title":"J Fungi"},{"key":"20841_CR14","unstructured":"CD4 \u00a6\u00a6. Omega Diagnostics [Internet]. [cited 2022 Nov 17]. https:\/\/www.omegadx.com\/Products\/Infectious-Diseases\/HIV\/CD4"},{"issue":"1","key":"20841_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12913-019-3948-x","volume":"19","author":"F Scorgie","year":"2019","unstructured":"Scorgie F, Mohamed Y, Anderson D, Crowe SM, Luchters S, Chersich MF. Qualitative assessment of South African healthcare worker perspectives on an instrument-free rapid CD4 test. BMC Health Serv Res. 2019;19(1):123.","journal-title":"BMC Health Serv Res"},{"key":"20841_CR16","unstructured":"Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis. How Far Are We to Use It? - PMC [Internet]. [cited 2023 Jun 13]. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8081860\/"},{"key":"20841_CR17","unstructured":"Lateral flow urine lipoarabinomannan assay (LF-LAM). for the diagnosis of active tuberculosis in people living with HIV, 2019 Update [Internet]. [cited 2023 Jun 13]. https:\/\/www.who.int\/publications-detail-redirect\/9789241550604"},{"key":"20841_CR18","unstructured":"Guidelines for the. Performance of CD4\u2009+\u2009T-Cell Determinations in Persons with Human Immunodeficiency Virus Infection [Internet]. [cited 2023 Jun 9]. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00019952.htm"},{"issue":"5","key":"20841_CR19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/QAI.0000000000003092","volume":"91","author":"K Lechiile","year":"2022","unstructured":"Lechiile K, Leeme TB, Tenforde MW, Bapabi M, Magwenzi J, Maithamako O, et al. Laboratory evaluation of the VISITECT Advanced Disease semiquantitative point-of-care CD4 test. JAIDS J Acquir Immune Defic Syndr. 2022;91(5):502\u20137.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"4","key":"20841_CR20","doi-asserted-by":"publisher","first-page":"e0230453","DOI":"10.1371\/journal.pone.0230453","volume":"15","author":"Z Ndlovu","year":"2020","unstructured":"Ndlovu Z, Massaquoi L, Bangwen NE, Batumba JN, Bora RU, Mbuaya J, et al. Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening. PLoS ONE. 2020;15(4):e0230453.","journal-title":"PLoS ONE"},{"key":"20841_CR21","unstructured":"World Health Organization. Summary of WHO prequalification assessment for VISITECT CD4 Advanced Disease [Internet]. World Health Organization. 2023. https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/whopr_files\/PQDx_0384-077-00_VISTECT-CD4_AdvancedDisease_v5.0.pdf"},{"key":"20841_CR22","unstructured":"Nakamaanya O. Evaluation of the Diagnostic Validity of the HIV VISITECT CD4 Point-of-Care Rapid Diagnostic Test Using PIMA Analyzer as the Gold Standard in Uganda. [Internet] [Thesis]. Makerere University; 2023 [cited 2024 Oct 25]. http:\/\/makir.mak.ac.ug\/handle\/10570\/12686"},{"issue":"3","key":"20841_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/14737159.2022.2048372","volume":"22","author":"MD Pham","year":"2022","unstructured":"Pham MD, Stoove M, Crowe S, Luchters S, Anderson D. A profile of the Visitect\u00ae CD4 and Visitect\u00ae CD4 advanced disease for management of people living with HIV. Expert Rev Mol Diagn. 2022;22(3):247\u201352.","journal-title":"Expert Rev Mol Diagn"},{"key":"20841_CR24","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach [Internet]. World Health Organization. 2021 [cited 2023 Jun 9]. xlii, 548 p. https:\/\/apps.who.int\/iris\/handle\/10665\/342899"},{"issue":"1","key":"20841_CR25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s12879-024-09682-6","volume":"24","author":"SA Sakyi","year":"2024","unstructured":"Sakyi SA, Kwarteng S, Senu E, Effah A, Opoku S, Oppong SA, et al. High prevalence of late presentation with advanced HIV disease and its predictors among newly diagnosed patients in Kumasi, Ghana. BMC Infect Dis. 2024;24(1):764.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"20841_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233\u201345.","journal-title":"N Engl J Med"},{"issue":"10","key":"20841_CR27","doi-asserted-by":"publisher","first-page":"e01032","DOI":"10.1128\/JCM.01032-20","volume":"58","author":"A Esmail","year":"2020","unstructured":"Esmail A, Pooran A, Sabur NF, Fadul M, Brar MS, Oelofse S, et al. An optimal diagnostic strategy for tuberculosis in hospitalized HIV-Infected patients using GeneXpert MTB\/RIF and Alere Determine TB LAM Ag. J Clin Microbiol. 2020;58(10):e01032\u201320.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"20841_CR28","doi-asserted-by":"publisher","first-page":"e0263172","DOI":"10.1371\/journal.pone.0263172","volume":"17","author":"A Simieneh","year":"2022","unstructured":"Simieneh A, Tadesse M, Kebede W, Gashaw M, Abebe G. Combination of Xpert\u00ae MTB\/RIF and DetermineTM TB-LAM Ag improves the diagnosis of extrapulmonary tuberculosis at Jimma University Medical Center, Oromia, Ethiopia. PLoS ONE. 2022;17(2):e0263172.","journal-title":"PLoS ONE"},{"issue":"9","key":"20841_CR29","doi-asserted-by":"publisher","first-page":"e0273970","DOI":"10.1371\/journal.pone.0273970","volume":"17","author":"S Acharya","year":"2022","unstructured":"Acharya S, Deshpande P, Asirvatham ES, Palkar A, Sarman CJ, Laxmeshwar C, et al. Utility of the lateral flow urine lipoarabinomannan tuberculosis assay in patients with advanced HIV disease at antiretroviral therapy centres in Mumbai, India. PLoS ONE. 2022;17(9):e0273970.","journal-title":"PLoS ONE"},{"key":"20841_CR30","doi-asserted-by":"crossref","unstructured":"Floridia M, Ciccacci F, Andreotti M, Hassane A, Sidumo Z, Magid N et al. Tuberculosis case finding with combined rapid point of care assays (Xpert\u00ae MTB\/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique. Clin Infect Dis off Publ Infect Dis Soc Am. 2017;65.","DOI":"10.1093\/cid\/cix641"},{"key":"20841_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijregi.2022.09.001","volume":"5","author":"G Diriba","year":"2022","unstructured":"Diriba G, Alemu A, Tola HH, Eshetu K, Yenew B, Amare M, et al. Detection of Mycobacterium tuberculosis and rifampicin resistance by Xpert\u00ae MTB\/RIF assay among presumptive tuberculosis patients in Addis Ababa, Ethiopia from 2014 to 2021. IJID Reg. 2022;5:97\u2013103.","journal-title":"IJID Reg"},{"key":"20841_CR32","doi-asserted-by":"crossref","unstructured":"Ezeanolue EE, Nwizu C, Greene GS, Amusu O, Chukwuka C, Ndembi N et al. Geographical Variation in Prevalence of Cryptococcal Antigenemia among HIV-infected Treatment-Na\u00efve Patients in Nigeria: A multicenter cross-sectional study. J Acquir Immune Defic Syndr. 1999. 2016;73(1):117.","DOI":"10.1097\/QAI.0000000000001048"},{"issue":"1","key":"20841_CR33","doi-asserted-by":"publisher","first-page":"e0001313","DOI":"10.1371\/journal.pgph.0001313","volume":"3","author":"RO Oladele","year":"2023","unstructured":"Oladele RO, Jordan AM, Okaa JU, Osaigbovo II, Shettima SA, Shehu NY, et al. A multicenter survey of asymptomatic cryptococcal antigenemia among patients with advanced HIV disease in Nigeria. PLOS Glob Public Health. 2023;3(1):e0001313.","journal-title":"PLOS Glob Public Health"},{"issue":"3","key":"20841_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5001\/omj.2012.51","volume":"27","author":"F Osazuwa","year":"2012","unstructured":"Osazuwa F, Dirisu JO, Okuonghae PE, Ugbebor O. Screening for Cryptococcal Antigenemia in Anti-retroviral Na\u00efve AIDS patients in Benin City, Nigeria. Oman Med J. 2012;27(3):228\u201331.","journal-title":"Oman Med J"},{"issue":"2","key":"20841_CR35","doi-asserted-by":"publisher","first-page":"ofw055","DOI":"10.1093\/ofid\/ofw055","volume":"3","author":"RO Oladele","year":"2016","unstructured":"Oladele RO, Akanmu AS, Nwosu AO, Ogunsola FT, Richardson MD, Denning DW. Cryptococcal antigenemia in Nigerian patients with Advanced Human Immunodeficiency Virus: influence of antiretroviral therapy adherence. Open Forum Infect Dis. 2016;3(2):ofw055.","journal-title":"Open Forum Infect Dis"},{"key":"20841_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fmicb.2018.00409","volume":"9","author":"E Temfack","year":"2018","unstructured":"Temfack E, Kouanfack C, Mossiang L, Loyse A, Fonkoua MC, Molloy SF, et al. Cryptococcal Antigen Screening in Asymptomatic HIV-Infected antiretroviral Na\u00efve patients in Cameroon and evaluation of the New Semi-quantitative Biosynex CryptoPS Test. Front Microbiol. 2018;9:409.","journal-title":"Front Microbiol"},{"issue":"4","key":"20841_CR37","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/trstmh\/trab124","volume":"116","author":"MA Elafros","year":"2022","unstructured":"Elafros MA, Belessiotis-Richards C, Birbeck GL, Bond V, Sikazwe I, Kvalsund MP. A qualitative study of patient, caregiver, doctor and nurse views of factors influencing lumbar puncture uptake in Zambia. Trans R Soc Trop Med Hyg. 2022;116(4):322\u20137.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7","key":"20841_CR38","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1016\/S2352-3018(20)30101-6","volume":"7","author":"Z Ndlovu","year":"2020","unstructured":"Ndlovu Z, Burton R, Stewart R, Bygrave H, Roberts T, Fajardo E, et al. Framework for the implementation of advanced HIV disease diagnostics in sub-saharan Africa: programmatic perspectives. Lancet HIV. 2020;7(7):e514\u201320.","journal-title":"Lancet HIV"},{"issue":"1","key":"20841_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12916-014-0173-7","volume":"12","author":"W Stevens","year":"2014","unstructured":"Stevens W, Gous N, Ford N, Scott LE. Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med. 2014;12(1):173.","journal-title":"BMC Med"},{"issue":"7","key":"20841_CR40","doi-asserted-by":"publisher","first-page":"e1002357","DOI":"10.1371\/journal.pmed.1002357","volume":"14","author":"SP Koenig","year":"2017","unstructured":"Koenig SP, Dorvil N, D\u00e9vieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLOS Med. 2017;14(7):e1002357.","journal-title":"PLOS Med"},{"issue":"11","key":"20841_CR41","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1097\/QAD.0b013e32833ac6bc","volume":"24","author":"CJ Hoffmann","year":"2010","unstructured":"Hoffmann CJ, Fielding KL, Charalambous S, Innes C, Chaisson RE, Grant AD, et al. Reducing mortality with co-trimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS Lond Engl. 2010;24(11):1709.","journal-title":"AIDS Lond Engl"},{"issue":"1","key":"20841_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAD.0b013e3280114ed7","volume":"21","author":"V Mulenga","year":"2007","unstructured":"Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS. 2007;21(1):77.","journal-title":"AIDS"},{"key":"20841_CR43","unstructured":"THE USE OF CO-TRIMOXAZOLE PROPHYLAXIS FOR HIV-RELATED INFECTIONS AMONG ADULTS. ADOLESCENTS AND CHILDREN. In: Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [Internet]. World Health Organization; 2014 [cited 2023 Jun 13]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK298965\/"},{"key":"20841_CR44","unstructured":"Federal Ministry of Health. 2019 HIV Sector Annual Report. 2019."},{"issue":"9","key":"20841_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/tropicalmed7090229","volume":"7","author":"GH Shah","year":"2022","unstructured":"Shah GH, Etheredge GD, Nkuta LM, Waterfield KC, Ikhile O, Ditekemena J, et al. Factors Associated with Retention of HIV patients on antiretroviral therapy in Care: evidence from Outpatient clinics in two provinces of the Democratic Republic of the Congo (DRC). Trop Med Infect Dis. 2022;7(9):229.","journal-title":"Trop Med Infect Dis"},{"key":"20841_CR46","unstructured":"FMOH. 2021 Annual Report HIV\/AIDS Health Sector Response in Nigeria. Federal Ministry of Health; 2021."},{"key":"20841_CR47","unstructured":"Predictors of All-Cause Mortality Among People With Human Immunodeficiency. Virus (HIV) in a Prospective Cohort Study in East Africa and Nigeria | Clinical Infectious Diseases | Oxford Academic [Internet]. [cited 2023 Jun 14]. https:\/\/academic.oup.com\/cid\/article\/75\/4\/657\/6448919"},{"issue":"suppl2","key":"20841_CR48","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/cid\/cix1141","volume":"66","author":"FA Post","year":"2018","unstructured":"Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, et al. Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial. Clin Infect Dis. 2018;66(suppl2):S132\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"20841_CR49","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","volume":"2","author":"S Croxford","year":"2017","unstructured":"Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health. 2017;2(1):e35\u201346.","journal-title":"Lancet Public Health"},{"key":"20841_CR50","unstructured":"NASCP, National HIVAIDS, Commodity. and Funding requirement 2023\u20132027. Federal Ministry of Health; 2023."},{"key":"20841_CR51","unstructured":"High acceptability and viral suppression rate for. first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria | PLOS ONE [Internet]. [cited 2023 Jun 14]. https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0284767"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20841-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-20841-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20841-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:08:12Z","timestamp":1733216892000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-20841-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["20841"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-20841-x","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for the study was secured from the National Health Research Ethics Committee of Nigeria with approval number NHREC\/01\/01\/2007-27\/01\/2021 as part of the operations research for the first phase of implementation of the AHD package of care in Nigeria. Participants were not subjected to any additional risk beyond that involved in receiving HIV treatment in Nigeria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3366"}}